DCs, derived from myeloid cells, can cross-present tumor antigens to T lymphocytes in draining lymph nodes (36), and studies have shown that DC-AdCCL21 cells modified by the CCL21 gene have resulted in extensive monocyte infiltration and significant reduction in tumor load (37). This evidence concerns the gene CCL21 and neoplasm.